ID   KK47/DDP10
AC   CVCL_8255
DR   CGH-DB; 9111-4
DR   Wikidata; Q54899982
RX   PubMed=9072542;
RX   PubMed=14973057;
RX   PubMed=29732388;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_8253 ! KK47
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 13
//
RX   PubMed=9072542; DOI=10.1016/S0022-5347(01)65140-1;
RA   Kotoh S., Naito S., Yokomizo A., Kohno K., Kuwano M., Kumazawa J.;
RT   "Enhanced expression of gamma-glutamylcysteine synthetase and
RT   glutathione S-transferase genes in cisplatin-resistant bladder cancer
RT   cells with multidrug resistance phenotype.";
RL   J. Urol. 157:1054-1058(1997).
//
RX   PubMed=14973057; DOI=10.1158/0008-5472.CAN-3263-2;
RA   Yasui K., Mihara S., Zhao C., Okamoto H., Saito-Ohara F., Tomida A.,
RA   Funato T., Yokomizo A., Naito S., Imoto I., Tsuruo T., Inazawa J.;
RT   "Alteration in copy numbers of genes as a mechanism for acquired drug
RT   resistance.";
RL   Cancer Res. 64:1403-1410(2004).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//